ClinicalTrials.gg
CompletedNCT00528424Updated Dec 2, 2017Results posted

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

A Phase 3 interventional study of AA4500 in Advanced Dupuytren's Disease, sponsored by Endo Pharmaceuticals. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-02.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
286
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Study AUX-CC-858 was an open-label continuation of the double-blind Study AUX-CC-857 (NCT00528606). Subjects who complete the Day 90 visit after their initial injection in Study AUX-CC-857 (NCT00528606) entered into Study AUX-CC-858. Subjects who required further treatment in Study AUX-CC-858, either because their treated metacarpophalangeal and/or proximal interphalangeal (PIP) joints did not have a reduction in contracture to 5° or less, the cord affecting that joint received less than three injections of AA4500, or they had other eligible cords that received no treatment in AUX-CC-857 (NCT00528606), had the option to receive up to five injections of AA4500 in this extension study. Subjects requiring further treatment were followed for efficacy and safety on Days 1, 7, and 30 after each injection, with injections separated by four weeks. Follow-up visits for the determination of efficacy and safety were conducted on Day 90, Month 6, and Month 9.

This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 (NCT00528606) and AUX-CC-859 (NCT00533273)) and 7 non-pivotal studies were evaluated.

02

Conditions studied

  • Advanced Dupuytren's Disease
03

In context

Lead sponsor

Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.

First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a diagnosis of advanced Dupuytren's disease, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100° for MP (80° for PIP) joints, caused by a palpable cord.
  • Had a positive "table top test," defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.
  • Were naïve to AA4500 treatment or had received only one or two injections of AA4500 for the treatment of advanced Dupuytren's disease in AUX-CC-857 ((NCT00528606).
  • Were judged to be in good health.
  • Must have participated in protocol AUX-CC-857 (NCT00528606).

Exclusion criteria

Exclusion Criteria:

  • Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.
  • Had received treatment for advanced Dupuytren's disease within 90 days of enrollment on the joint selected for the initial injection of AA4500, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon.
  • Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
286 participants (actual)

Study arms

  • Experimental
    AA4500 0.58 mg

    Biological: AA4500

Interventions

  • BiologicalAA4500

    Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.

    Also known as: XIAFLEX®

06

What researchers measure

Primary outcomes

  1. Reduction in Contracture to 5° or Less

    Successfully treated or clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.

    Time frame: Within 30 days after last injection

Secondary outcomes

  1. Clinical Improvement After the Last Injection

    Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection

    Time frame: Baseline, within 30 days after last injection

  2. Percent Reduction From Baseline Contracture After the Last Injection

    Percent change in degree of contracture in non-primary joints measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture.

    Time frame: Baseline, Day 30 after last injection

  3. Change From Baseline Range of Motion After the Last Injection

    Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion - baseline range of motion

    Time frame: Baseline, Day 30 after last injection

  4. Time to Reach Clinical Success

    Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories

    Time frame: Within 30 days after last injection

  5. Clinical Success After the First Injection

    Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.

    Time frame: Within 30 days after first injection

  6. Clinical Improvement After the First Injection

    Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection

    Time frame: Baseline, within 30 days after first injection

  7. Percent Reduction From Baseline Contracture After the First Injection

    Percent change in degree of contracture in non-primary joints measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture.

    Time frame: Baseline, Day 30 after first injection

  8. Change From Baseline Range of Motion After the First Injection

    Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion - baseline range of motion

    Time frame: Baseline, Day 30 after first injection

07

Results

Posted Oct 22, 2010

Participant flow

Participant flow — Overall Study
MilestoneAA4500 0.58 mg
Started286
Completed257
Not completed29
Withdrew: Lost to follow-up13
Withdrew: Withdrew consent2
Withdrew: Administrative reason2
Withdrew: Other12

Outcome measures

PrimaryReduction in Contracture to 5° or Less

Successfully treated or clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.

Time frame:
Within 30 days after last injection
Reported as:
Number · Percentage of joints
Reduction in Contracture to 5° or Less
Percentage of jointsAA4500 0.58 mg
Reduction in Contracture to 5° or Less41.9
SecondaryClinical Improvement After the Last Injection

Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection

Time frame:
Baseline, within 30 days after last injection
Reported as:
Number · Percentage of joints
Clinical Improvement After the Last Injection
Percentage of jointsAA4500 0.58 mg
Clinical Improvement After the Last Injection65.0
SecondaryPercent Reduction From Baseline Contracture After the Last Injection

Percent change in degree of contracture in non-primary joints measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture.

Time frame:
Baseline, Day 30 after last injection
Reported as:
Mean · Percentage of change
Percent Reduction From Baseline Contracture After the Last Injection
Percentage of changeAA4500 0.58 mg
Percent Reduction From Baseline Contracture After the Last Injection60.8 ± 39.00
SecondaryChange From Baseline Range of Motion After the Last Injection

Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion - baseline range of motion

Time frame:
Baseline, Day 30 after last injection
Reported as:
Mean · Degrees
Change From Baseline Range of Motion After the Last Injection
DegreesAA4500 0.58 mg
Change From Baseline Range of Motion After the Last Injection24.0 ± 20.83
SecondaryTime to Reach Clinical Success

Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories

Time frame:
Within 30 days after last injection
Reported as:
Number · Percentage of Joints
Time to Reach Clinical Success
Percentage of JointsAA4500 0.58 mg
Injection 1, Day 112.5
Injection 1, Day 715.9
Injection 1, Day 305.9
Injection 2, Day 00.0
Injection 2, Day 12.2
Injection 2, Day 71.3
Injection 2, Day 301.9
Injection 3, Day 00.0
Injection 3, Day 11.3
Injection 3, Day 70.6
Injection 3, Day 300.3
Did not reach Clinical Success58.1
SecondaryClinical Success After the First Injection

Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.

Time frame:
Within 30 days after first injection
Reported as:
Number · Percentage of Joints
Clinical Success After the First Injection
Percentage of JointsAA4500 0.58 mg
Clinical Success After the First Injection34.1
SecondaryClinical Improvement After the First Injection

Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection

Time frame:
Baseline, within 30 days after first injection
Reported as:
Number · Percentage of Joints
Clinical Improvement After the First Injection
Percentage of JointsAA4500 0.58 mg
Clinical Improvement After the First Injection56.3
SecondaryPercent Reduction From Baseline Contracture After the First Injection

Percent change in degree of contracture in non-primary joints measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture.

Time frame:
Baseline, Day 30 after first injection
Reported as:
Mean · Percentage of change
Percent Reduction From Baseline Contracture After the First Injection
Percentage of changeAA4500 0.58 mg
Percent Reduction From Baseline Contracture After the First Injection53.9 ± 38.64
SecondaryChange From Baseline Range of Motion After the First Injection

Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion - baseline range of motion

Time frame:
Baseline, Day 30 after first injection
Reported as:
Mean · Degrees
Change From Baseline Range of Motion After the First Injection
DegreesAA4500 0.58 mg
Change From Baseline Range of Motion After the First Injection20 ± 19.46

Adverse events

Collected over From the time of study drug administration until 30 days after completion of or discharge from the study. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AA4500 0.58 mg—9/286 (3.1%)171/286 (59.8%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventAA4500 0.58 mg
Abdominal painGastrointestinal disorders1/286
Acute myocardial infarctionCardiac disorders1/286
AstheniaGeneral disorders1/286
Chronic myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/286
Clostridial infectionInfections and infestations1/286
Finger deformityMusculoskeletal and connective tissue disorders1/286
MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/286
NauseaGastrointestinal disorders1/286
NephrolithiasisRenal and urinary disorders1/286
PneumonitisRespiratory, thoracic and mediastinal disorders1/286
Most frequent other events
Showing 10 of 14
Most frequent other events
EventAA4500 0.58 mg
Oedema peripheralGeneral disorders136/286
ContusionInjury, poisoning and procedural complications95/286
Pain in extremityMusculoskeletal and connective tissue disorders66/286
Injection site haemorrhageGeneral disorders52/286
Injection site painGeneral disorders47/286
TendernessGeneral disorders43/286
EcchymosisSkin and subcutaneous tissue disorders39/286
Injection site swellingGeneral disorders34/286
PruritusSkin and subcutaneous tissue disorders33/286
Skin lacerationInjury, poisoning and procedural complications24/286

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AA4500 0.58 mg
<=18 years0
Between 18 and 65 years166
>=65 years120
Age, Continuous
Age, Continuous(years)AA4500 0.58 mg
Mean62.7 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)AA4500 0.58 mg
Female60
Male226
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)AA4500 0.58 mg
White285
Hispanic1
Region of Enrollment
Region of Enrollment(participants)AA4500 0.58 mg
United States286
08

Study locations

15 sites
  • 100 UCLA Medical Plaza, Suite 305
    Los Angeles, California 90095, United States
  • Hand Surgery Clinic
    Palo Alto, California 94304, United States
  • Hand Surgery Associates, PC
    Denver, Colorado 80210, United States
  • The Hand and Upper Extremity Center of Georgia, P.C.
    Atlanta, Georgia 30342, United States
  • Rockford Orthopedic Associates, Ltd.
    Rockford, Illinois 61107, United States
  • The Indiana Hand Center
    Indianapolis, Indiana 46260, United States
  • Brigham and Women's Hospital, Department of Orthopedic Surgery
    Boston, Massachusetts 02115, United States
  • Newton-Wellesley Hospital
    Newton, Massachusetts 02462, United States
  • TRIA Orthopaedic Center
    Minneapolis, Minnesota 55431, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • SUNY Stony Brook - Department of Orthopedics
    Stony Brook, New York 11794, United States
  • Health Research Institute
    Oklahoma City, Oklahoma 73109, United States
  • Hand Microsurgery & Reconstructive Orthopaedics
    Erie, Pennsylvania 16550, United States
  • University Orthopedics Center
    State College, Pennsylvania 16801, United States
  • Department of Orthopaedics, Brown University, Rhode Island Hospital
    Providence, Rhode Island 02905, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2007 to primary completion in Nov 2008, 11 months.

Results were first posted in Oct 2010, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2007
First posted
Sep 12, 2007
StartActual
Dec 2007
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Oct 22, 2010
Last update
Dec 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00528424
Responsible party
Sponsor
First posted
Sep 12, 2007
Start date
Dec 2007
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Oct 22, 2010
Last update
Dec 2, 2017

Study contacts

Veronica Urdaneta, MD
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion